Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL664690 | 0.98 | CA12 (0.53) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL18231989 | 0.89 | MAPK1 (0.48) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL18912608 | 0.87 | MAPK1 (0.49) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL28719503 | 0.84 | MEN1 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL22343645 | 0.84 | HDAC2 (0.49) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL22710006 | 0.83 | CA12 (0.56) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL730168 | 0.82 | HSD17B10 (0.54) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL793119 | 0.82 | MEN1 (0.57) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL3366797 | 0.82 | MAPK1 (0.41) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL3159614 | 0.81 | CA12 (0.54) | CA12CA1CA2CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160334364-A1 | GEL FOR USE IN POLYACRYLAMIDE GEL ELECTROPHORESIS AND ELECTROPHORESIS DEVICE USING SAID GEL | SHARP KABUSHIKI KAISHA (JP) | 2016-11-17 | — | — | US | disclosed |
| EP-2124869-B1 | POLYMER PARTICLE DISPERSION, COMPOSITION CONTAINING THE SAME AND COSMETIC TREATMENT METHOD | OREAL (FR) | 2012-08-15 | — | — | EP | disclosed |
| US-20100166844-A1 | POLYMER PARTICLE DISPERSION, COMPOSITION CONTAINING THE SAME AND COSMETIC TREATMENT METHOD | L'OREAL S.A. (FR) | 2010-07-01 | — | — | US | disclosed |
| US-20100166844-A1 | POLYMER PARTICLE DISPERSION, COMPOSITION CONTAINING THE SAME AND COSMETIC TREATMENT METHOD | L'OREAL S.A. (FR) | 2010-07-01 | — | — | US | disclosed |
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | disclosed |
| WO-2008104698-A2 | POLYMER PARTICLE DISPERSION, COMPOSITION CONTAINING THE SAME AND COSMETIC TREATMENT METHOD | L'OREAL (FR) | 2008-09-04 | — | — | WO | disclosed |
| EP-1572678-A4 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARM INC (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1218353-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| EP-1572678-A2 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1272185-B1 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| EP-0415055-B1 | Water-soluble pressure-sensitive skin adhesive | ROEHM GMBH (DE) | 1994-12-14 | — | — | EP | disclosed |
| US-5133970-A | WATER-SOLUBLE PRESSURE-SENSITIVE SKIN-ADHESIVE AND USE THEREOF | ROHM GMBH CHEMISCHE FABRIK (DE) | 1992-07-28 | — | — | US | disclosed |
| EP-0415055-A2 | Water-soluble pressure-sensitive skin adhesive | RÖHM GMBH (DE) | 1991-03-06 | — | — | EP | disclosed |
| US-4206144-A | N,N-Dialkyl-N-aminoalkyl-N-(amino or nitro)phenylalkyl- and N-methyl-N-[3-(amino or nitro)phenoxy-2-hydroxy-1-propyl]-N,N-bis(3-aminopropyl)quaternary ammonium salts | STERLING DRUG INC. (US) | 1980-06-03 | — | — | US | disclosed |
| US-4146558-A | Azo dyestuff intermediate nitro- or aminobenzenes ring-substituted by a quaternized amine alkyl or amino-alkoxy group | STERLING DRUG INC. (US) | 1979-03-27 | — | — | US | disclosed |
| US-4112207-A | Radiation-curable polymers bearing quaternary nitrogen groups | THE DOW CHEMICAL COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4103092-A | Water-soluble quaternary ammonium non-heterocyclic azo dyestuffs | STERLING DRUG INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4065500-A | Water-soluble quaternary ammonium azo dyestuffs | STERLING DRUG INC. (US) | 1977-12-27 | — | — | US | disclosed |
| US-3996282-A | Water-soluble quaternary ammonium dyestuffs | STERLING DRUG INC. (US) | 1976-12-07 | — | — | US | disclosed |
| US-3935182-A | Water-soluble quaternary ammonium heterocyclic azo dyestuffs | STERLING DRUG INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166844-A1 | POLYMER PARTICLE DISPERSION, COMPOSITION CONTAINING THE SAME AND COSMETIC TREATMENT METHOD | KRT18, KRTCAP2, DSG1 | CA12 1542/4885CA1 3980/4885CA2 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.